Bioequivalence study of dihydroartemisinin-piperaquine (DHP) generic formulation in fixed-dose combination, in healthy Indonesian volunteers
<p><strong>Background: </strong>Malaria is still considered as a major health problem in the world including in Indonesia, which is regarded as one of the malaria-endemic countries. Since 2006, WHO has recommended the use of artemisinin-based combination therapy (ACT) to treat unco...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
DiscoverSys
2018-08-01
|
Series: | Bali Medical Journal |
Subjects: | |
Online Access: | https://balimedicaljournal.org/index.php/bmj/article/view/822 |
id |
doaj-c9318ad8a833471f90b7302ec7bf609a |
---|---|
record_format |
Article |
spelling |
doaj-c9318ad8a833471f90b7302ec7bf609a2020-11-25T02:25:02ZengDiscoverSysBali Medical Journal2089-11802302-29142018-08-017229029510.15562/bmj.v7i2.822466Bioequivalence study of dihydroartemisinin-piperaquine (DHP) generic formulation in fixed-dose combination, in healthy Indonesian volunteersAni IsnawatiRetno GitawatiMariana RainiIndri RooslamiatiLanny MarlianyEffi SetiawatiVivi Setiawaty<p><strong>Background: </strong>Malaria is still considered as a major health problem in the world including in Indonesia, which is regarded as one of the malaria-endemic countries. Since 2006, WHO has recommended the use of artemisinin-based combination therapy (ACT) to treat uncomplicated falciparum malaria. In Indonesia, DHP tablet (combination of dihydroartemisinin and piperaquine) is the first line therapy used in malaria control program, which currently used imported DHP tablet. To produce generic DHP tablet, comparative bioequivalence test between DHP tablet and the drug previously used is needed. <strong>Methods: </strong>A single dosed, randomized, double-blinded, one-period, and parallel study design was conducted in the present research. Every twenty-four subjects were assigned into two groups, which are test group and comparison group. <strong>Results: </strong>The results showed that even though in vitro comparison of dissolution test has fulfilled the requirements, in vivo test results has not fulfilled the bioequivalence standards. Obtained geometric mean ratios (90% confidence intervals) of the test drug to comparator drug for dihydroartemisinin were 83.30% (67.06%–103.48%) for AUC<sub>0-t</sub>, 83.24% (67.10%–103.26%) for AUC<sub>0-inf</sub>, and 75.67% (61.83%–92.61%) for C<sub>max</sub>. The geometric mean ratios (90% confidence intervals) of the test drug to comparator drug for piperaquine were 97.31% (76.50%–123.80%) for AUC<sub>0-t</sub>, 94.18% (74.18%–119.59%) for AUC<sub>0-inf</sub>, and 96.47% (71.80%–129.62%) for C<sub>max</sub>. <strong>Conclusions: </strong>Therefore, the pharmacokinetic profile of the test drug is concluded to be bio-inequivalent with the comparator drug.</p>https://balimedicaljournal.org/index.php/bmj/article/view/822dihydroartemisininpiperaquinepharmacokineticsbioequivalence |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ani Isnawati Retno Gitawati Mariana Raini Indri Rooslamiati Lanny Marliany Effi Setiawati Vivi Setiawaty |
spellingShingle |
Ani Isnawati Retno Gitawati Mariana Raini Indri Rooslamiati Lanny Marliany Effi Setiawati Vivi Setiawaty Bioequivalence study of dihydroartemisinin-piperaquine (DHP) generic formulation in fixed-dose combination, in healthy Indonesian volunteers Bali Medical Journal dihydroartemisinin piperaquine pharmacokinetics bioequivalence |
author_facet |
Ani Isnawati Retno Gitawati Mariana Raini Indri Rooslamiati Lanny Marliany Effi Setiawati Vivi Setiawaty |
author_sort |
Ani Isnawati |
title |
Bioequivalence study of dihydroartemisinin-piperaquine (DHP) generic formulation in fixed-dose combination, in healthy Indonesian volunteers |
title_short |
Bioequivalence study of dihydroartemisinin-piperaquine (DHP) generic formulation in fixed-dose combination, in healthy Indonesian volunteers |
title_full |
Bioequivalence study of dihydroartemisinin-piperaquine (DHP) generic formulation in fixed-dose combination, in healthy Indonesian volunteers |
title_fullStr |
Bioequivalence study of dihydroartemisinin-piperaquine (DHP) generic formulation in fixed-dose combination, in healthy Indonesian volunteers |
title_full_unstemmed |
Bioequivalence study of dihydroartemisinin-piperaquine (DHP) generic formulation in fixed-dose combination, in healthy Indonesian volunteers |
title_sort |
bioequivalence study of dihydroartemisinin-piperaquine (dhp) generic formulation in fixed-dose combination, in healthy indonesian volunteers |
publisher |
DiscoverSys |
series |
Bali Medical Journal |
issn |
2089-1180 2302-2914 |
publishDate |
2018-08-01 |
description |
<p><strong>Background: </strong>Malaria is still considered as a major health problem in the world including in Indonesia, which is regarded as one of the malaria-endemic countries. Since 2006, WHO has recommended the use of artemisinin-based combination therapy (ACT) to treat uncomplicated falciparum malaria. In Indonesia, DHP tablet (combination of dihydroartemisinin and piperaquine) is the first line therapy used in malaria control program, which currently used imported DHP tablet. To produce generic DHP tablet, comparative bioequivalence test between DHP tablet and the drug previously used is needed. <strong>Methods: </strong>A single dosed, randomized, double-blinded, one-period, and parallel study design was conducted in the present research. Every twenty-four subjects were assigned into two groups, which are test group and comparison group. <strong>Results: </strong>The results showed that even though in vitro comparison of dissolution test has fulfilled the requirements, in vivo test results has not fulfilled the bioequivalence standards. Obtained geometric mean ratios (90% confidence intervals) of the test drug to comparator drug for dihydroartemisinin were 83.30% (67.06%–103.48%) for AUC<sub>0-t</sub>, 83.24% (67.10%–103.26%) for AUC<sub>0-inf</sub>, and 75.67% (61.83%–92.61%) for C<sub>max</sub>. The geometric mean ratios (90% confidence intervals) of the test drug to comparator drug for piperaquine were 97.31% (76.50%–123.80%) for AUC<sub>0-t</sub>, 94.18% (74.18%–119.59%) for AUC<sub>0-inf</sub>, and 96.47% (71.80%–129.62%) for C<sub>max</sub>. <strong>Conclusions: </strong>Therefore, the pharmacokinetic profile of the test drug is concluded to be bio-inequivalent with the comparator drug.</p> |
topic |
dihydroartemisinin piperaquine pharmacokinetics bioequivalence |
url |
https://balimedicaljournal.org/index.php/bmj/article/view/822 |
work_keys_str_mv |
AT aniisnawati bioequivalencestudyofdihydroartemisininpiperaquinedhpgenericformulationinfixeddosecombinationinhealthyindonesianvolunteers AT retnogitawati bioequivalencestudyofdihydroartemisininpiperaquinedhpgenericformulationinfixeddosecombinationinhealthyindonesianvolunteers AT marianaraini bioequivalencestudyofdihydroartemisininpiperaquinedhpgenericformulationinfixeddosecombinationinhealthyindonesianvolunteers AT indrirooslamiati bioequivalencestudyofdihydroartemisininpiperaquinedhpgenericformulationinfixeddosecombinationinhealthyindonesianvolunteers AT lannymarliany bioequivalencestudyofdihydroartemisininpiperaquinedhpgenericformulationinfixeddosecombinationinhealthyindonesianvolunteers AT effisetiawati bioequivalencestudyofdihydroartemisininpiperaquinedhpgenericformulationinfixeddosecombinationinhealthyindonesianvolunteers AT vivisetiawaty bioequivalencestudyofdihydroartemisininpiperaquinedhpgenericformulationinfixeddosecombinationinhealthyindonesianvolunteers |
_version_ |
1724853123953983488 |